Pravachol OTC Deal Reached Between Bayer, Bristol
This article was originally published in The Tan Sheet
Executive Summary
Bayer is following through on its aim to become the preeminent switch player through a deal with Bristol-Myers Squibb for OTC Pravachol in the U.S